Published in J Neurochem on December 01, 1976
Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci U S A (1981) 1.78
Neuroprotective activity of a new class of steroidal inhibitors of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A (1997) 0.94
Pregnenolone sulfate potentiates the inwardly rectifying K channel Kir2.3. PLoS One (2009) 0.81
The eukaryotic enzyme Bds1 is an alkyl but not an aryl sulfohydrolase. Biochem Biophys Res Commun (2017) 0.75
Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex (2000) 3.69
A glycolipid on the surface of mouse natural killer cells. Eur J Immunol (1980) 3.13
Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci U S A (1981) 2.83
Experimental investigation of geologically produced antineutrinos with KamLAND. Nature (2005) 2.75
Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders. Nat Genet (1995) 2.62
MR findings in adult-onset adrenoleukodystrophy. AJNR Am J Neuroradiol (1995) 2.42
A unified nomenclature for peroxisome biogenesis factors. J Cell Biol (1996) 2.25
Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil. Ann Neurol (1993) 2.07
Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol (1999) 2.06
Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology (2003) 1.92
Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J (1991) 1.84
Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy. Ann Neurol (1984) 1.83
Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology (1981) 1.81
Ototoxicity of neomycin and its penetration through the round window membrane into the perilymph. Ann Otol Rhinol Laryngol (1986) 1.80
Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy. Neurology (2005) 1.77
Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci U S A (1984) 1.75
Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol (2001) 1.71
Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts. Ann Neurol (1980) 1.71
Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA (1995) 1.69
Hyperornithinemia, hyperammonemia, and homocitrullinuria. A new disorder of amino acid metabolism associated with myoclonic seizures and mental retardation. Am J Dis Child (1969) 1.65
The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. EMBO J (1996) 1.62
F-SSCP: fluorescence-based polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis. PCR Methods Appl (1992) 1.58
The cerebrohepatorenal (Zellweger) syndrome. Increased levels and impaired degradation of very-long-chain fatty acids and their use in prenatal diagnosis. N Engl J Med (1984) 1.56
A new ultimate anus-preserving operation for extremely low rectal cancer and for anal canal cancer. Tech Coloproctol (2003) 1.52
A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry. Am J Obstet Gynecol (1989) 1.49
Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet (1986) 1.47
Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am J Med Genet (1998) 1.47
Measurement of neutrino oscillation with KamLAND: evidence of spectral distortion. Phys Rev Lett (2005) 1.46
Complementation study of peroxisome-deficient disorders by immunofluorescence staining and characterization of fused cells. Hum Genet (1992) 1.46
ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat (2001) 1.45
Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders. Nat Genet (1997) 1.44
Bmp activity establishes a gradient of positional information throughout the entire neural plate. Development (1999) 1.44
A facile synthesis of ceramides. Chem Phys Lipids (1975) 1.43
Identification of three distinct peroxisomal protein import defects in patients with peroxisome biogenesis disorders. J Cell Sci (1995) 1.40
Cerebro-hepato-renal (Zellweger) syndrome and neonatal adrenoleukodystrophy: similarities in phenotype and accumulation of very long chain fatty acids. Johns Hopkins Med J (1982) 1.39
Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. Science (1984) 1.39
Identification of glycolipid receptors for Helicobacter pylori by TLC-immunostaining. FEBS Lett (1991) 1.37
Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol (1998) 1.35
Saposin A: second cerebrosidase activator protein. Proc Natl Acad Sci U S A (1989) 1.35
Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology (1999) 1.34
Frequent alterations of visual pigment genes in adrenoleukodystrophy. Am J Hum Genet (1988) 1.32
Identification of PEX10, the gene defective in complementation group 7 of the peroxisome-biogenesis disorders. Am J Hum Genet (1998) 1.31
Metabolic control of peroxisome abundance. J Cell Sci (1999) 1.31
Standardization of complementation grouping of peroxisome-deficient disorders and the second Zellweger patient with peroxisomal assembly factor-1 (PAF-1) defect. Am J Hum Genet (1993) 1.29
K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res (1994) 1.28
The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol (1992) 1.27
Characterization of "clearance" factor and "cell-bound" antibody in experimental typhoid. J Bacteriol (1966) 1.26
Identification of prosaposin as a neurotrophic factor. Proc Natl Acad Sci U S A (1994) 1.25
Adrenoleukodystrophy: studies of the phenotype, genetics and biochemistry. Johns Hopkins Med J (1980) 1.23
Distribution of saposin proteins (sphingolipid activator proteins) in lysosomal storage and other diseases. Proc Natl Acad Sci U S A (1990) 1.22
Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res (1984) 1.21
Linkage of adrenoleukodystrophy to a polymorphic DNA probe. Ann Neurol (1987) 1.20
A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A (1997) 1.20
Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol (2001) 1.19
Apparent biochemical homozygosity in two obligatory heterozygotes for metachromatic leukodystrophy. J Pediatr (1976) 1.19
Interaction between Clostridium botulinum neurotoxin and gangliosides. Biochim Biophys Acta (1980) 1.18
Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. J Clin Invest (1995) 1.18
Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol (2000) 1.17
Solubilization and partial purification of steroid sulfatase from rat liver: characterization of estrone sulfatase. Arch Biochem Biophys (1976) 1.16
Peroxisomal defects in neonatal-onset and X-linked adrenoleukodystrophies. Science (1985) 1.15
Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment. Curr Opin Neurol (2001) 1.15
Binding and transport of gangliosides by prosaposin. Proc Natl Acad Sci U S A (1992) 1.15
Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands. Hum Pathol (1996) 1.15
Turnover of the fatty acids of rat brain gangliosides, glycerophosphatides, cerebrosides, and sulfatides as a function of age. J Lipid Res (1965) 1.15
Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase. Biochim Biophys Acta (1975) 1.15
Antiglycolipid autoantibody detected in the sera from systemic lupus erythematosus patients. J Clin Invest (1980) 1.14
TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids. FEBS Lett (1986) 1.13
Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes Res Clin Pract (1990) 1.13
Saposin D: a sphingomyelinase activator. Biochem Biophys Res Commun (1988) 1.12
Role of sulfatides in adhesion of Helicobacter pylori to gastric cancer cells. Infect Immun (1996) 1.11
Fatty acid synthetase of brain: development, influence of nutritional and hormonal factors and comparison with liver enzyme. J Neurochem (1972) 1.11
Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochem Res (1999) 1.11
Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): its mechanism and inhibition by ganglioside. Arch Biochem Biophys (1997) 1.10
Identification of a fatty acid delta6-desaturase deficiency in human skin fibroblasts. J Lipid Res (2001) 1.10
Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect. Proc Natl Acad Sci U S A (1990) 1.10
Identification of the neurotrophic factor sequence of prosaposin. FASEB J (1995) 1.08
Peroxisomal bifunctional protein deficiency revisited: resolution of its true enzymatic and molecular basis. Am J Hum Genet (1999) 1.08
Altered expression of ALDP in X-linked adrenoleukodystrophy. Am J Hum Genet (1995) 1.08
Ceramidase deficiency in Farber's disease (lipogranulomatosis). Science (1972) 1.08
Cerebroside galactosidase of brain. J Lipid Res (1966) 1.07
Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA (1995) 1.07
Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Mol Genet Metab (1999) 1.07
Hyperuricemia in Down's syndrome. J Clin Endocrinol Metab (1968) 1.07
A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann Neurol (1987) 1.06
Adrenoleukodystrophy: impaired oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex. Biochem Biophys Res Commun (1981) 1.06
Absence of insulitis and overt diabetes in athymic nude mice with NOD genetic background. Jikken Dobutsu (1986) 1.06
Familial X-linked Addison disease as an expression of adrenoleukodystrophy (ALD): elevated C26 fatty acid in cultured skin fibroblasts. Neurology (1982) 1.05
High concentration of hexacosanoate in cultured skin fibroblast lipids from adrenoleukodystrophy patients. Biochem Biophys Res Commun (1978) 1.05
Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant (2000) 1.05
Nerve conduction studies in adrenomyeloneuropathy. J Neurol Neurosurg Psychiatry (1996) 1.05
Molecular genetic changes found in human lung cancer and its precursor lesions. Cold Spring Harb Symp Quant Biol (1994) 1.04
Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia. Br J Haematol (1989) 1.03